Cerevel Therapeutics Holdings, Inc.

CERE · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$433-$352-$225-$152
Dep. & Amort.$6$5$3$0
Deferred Tax-$2$0$4$3
Stock-Based Comp.$69$39$24$11
Change in WC$16$28$16$18
Other Non-Cash$1-$13$1$2
Operating Cash Flow-$342-$293-$179-$118
Investing Activities
PP&E Inv.-$4-$4-$11-$19
Net Acquisitions-$0$0$0$0
Inv. Purchases-$865-$888-$425$0
Inv. Sales/Matur.$943$503$0$0
Other Inv. Act.$0-$0-$0$0
Investing Cash Flow$74-$389-$436-$19
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$518$251$328$6
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$549$623$424$441
Financing Cash Flow$549$623$424$441
Forex Effect$549$0$0$0
Net Chg. in Cash$99-$59-$191$304
Supplemental Information
Beg. Cash$892$197$388$84
End Cash$991$138$197$388
Free Cash Flow-$346-$297-$189-$137